Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor

This is the first report in which crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor, reduced an atypical carcinoid tumor with ALK rearrangement. A 70-year-old man developed a tumor in the left lung and multiple metastases to the lung and brain. The pathology of transbronchial biopsied specim...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakajima, Masayuki, Uchiyama, Naoki, Shigemasa, Rie, Matsumura, Takeshi, Matsuoka, Ryota, Nomura, Akihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5140865/
https://www.ncbi.nlm.nih.gov/pubmed/27803410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5140865/
https://www.ncbi.nlm.nih.gov/pubmed/27803410

Ejemplares similares